Based on this, we could speculate that the MTE treatment suppressed the malignant behaviors of glioma cells through upregulating lncMEG3, reducing miR‐542‐3p expression, and finally upregulating SFRP1 expression. The gene discussed is SFRP1; the disease is central nervous system cancer.